- Home
- RNAZ vs EFSH Comparison
RNAZ vs EFSH Comparison
Compare RNAZ & EFSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- EFSH
- Stock Information
- Founded
- RNAZ 2016
- EFSH 1948
- Country
- RNAZ United States
- EFSH United States
- Employees
- RNAZ N/A
- EFSH N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- EFSH Professional Services
- Sector
- RNAZ Health Care
- EFSH Consumer Discretionary
- Exchange
- RNAZ Nasdaq
- EFSH Nasdaq
- Market Cap
- RNAZ 4.9M
- EFSH 4.2M
- IPO Year
- RNAZ 2021
- EFSH N/A
- Fundamental
- Price
- RNAZ $3.35
- EFSH $0.23
- Analyst Decision
- RNAZ Strong Buy
- EFSH
- Analyst Count
- RNAZ 1
- EFSH 0
- Target Price
- RNAZ $20.00
- EFSH N/A
- AVG Volume (30 Days)
- RNAZ 143.7K
- EFSH 3.9M
- Earning Date
- RNAZ 11-14-2024
- EFSH 11-19-2024
- Dividend Yield
- RNAZ N/A
- EFSH N/A
- EPS Growth
- RNAZ N/A
- EFSH N/A
- EPS
- RNAZ N/A
- EFSH N/A
- Revenue
- RNAZ N/A
- EFSH $69,415,140.00
- Revenue This Year
- RNAZ N/A
- EFSH N/A
- Revenue Next Year
- RNAZ N/A
- EFSH N/A
- P/E Ratio
- RNAZ N/A
- EFSH N/A
- Revenue Growth
- RNAZ N/A
- EFSH 228.22
- 52 Week Low
- RNAZ $2.66
- EFSH $0.20
- 52 Week High
- RNAZ $66.33
- EFSH $820.95
- Technical
- Relative Strength Index (RSI)
- RNAZ 30.32
- EFSH 39.61
- Support Level
- RNAZ $2.90
- EFSH $0.22
- Resistance Level
- RNAZ $3.50
- EFSH $0.32
- Average True Range (ATR)
- RNAZ 0.42
- EFSH 0.04
- MACD
- RNAZ 0.31
- EFSH 0.22
- Stochastic Oscillator
- RNAZ 50.74
- EFSH 15.83
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About EFSH 1847 Holdings LLC
1847 Holdings LLC is a diversified holding company. It operates in Four segments: Retail and appliances, Retail and Eyewear, Construction, and Automotive Supplies. The company generates maximum revenue from the Construction segment. The firm, through its subsidiaries, provides a wide range of land application services and sells equipment and parts, primarily to the agricultural, construction, and lawn and garden industries.